NCT03206203: Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer

NCT03206203
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Leptomeningeal disease; Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases- see trial for details; Male patients
https://ClinicalTrials.gov/show/NCT03206203

Comments are closed.

Up ↑